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Abstract
Sexual HIV-1 transmission by vaginal route is the most predominant mode of viral transmission, resulting in millions of new
infections every year. In the absence of an effective vaccine, there is an urgent need to develop other alternative methods of
pre-exposure prophylaxis (PrEP). Many novel drugs that are currently approved for clinical use also show great potential to
prevent viral sexual transmission when administered systemically. A small animal model that permits rapid preclinical
evaluation of potential candidates for their systemic PrEP efficacy will greatly enhance progress in this area of investigation.
We have previously shown that RAG-hu humanized mouse model permits HIV-1 mucosal transmission via both vaginal and
rectal routes and displays CD4 T cell loss typical to that seen in the human. Thus far systemic PrEP studies have been
primarily limited to RT inhibitors exemplified by tenofovir and emtricitabine. In these proof-of-concept studies we evaluated
two new classes of clinically approved drugs with different modes of action namely, an integrase inhibitor raltegravir and a
CCR5 inhibitor maraviroc as potential systemically administered chemo-prophylactics. Our results showed that oral
administration of either of these drugs fully protects against vaginal HIV-1 challenge in the RAG-hu mouse model. Based on
these results both these drugs show great promise for further development as orally administered PrEPs.
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Introduction
With no effective HIV vaccine on the horizon, alternative
preventive methods are urgently needed to stem the AIDS
epidemic [1]. Although use of condoms can substantially reduce
viral transmission, lack of full compliance has been a significant
issue [2]. This is especially true in many developing countries
where the HIV prevalence is high and condoms are not widely
available and/or the compliance is low. Male circumcision has
shown reduced viral transmission to men but this does not prevent
infection of women [3]. An effective pre-exposure prophylactic
(PrEP) that can prevent sexual transmission of HIV-1 is likely to
play a major role in preventing millions of new cases [4]. It will
also empower women to protect themselves from the HIV risk.
The benefits of PrEP in the infectious disease field have been
already well documented for the prevention of malaria and
mother-to-child transmission in the case of HIV [5,6,7]. An
effective PrEP, when available, is estimated to prevent 2.7 to 3.2
million new infections in sub-Saharan Africa and thousands of new
cases in the high risk individuals in the USA [8].
Currently there are numerous clinically approved effective anti-
retroviral drugs that are used to treat the HIV infection and some
of these can be potentially exploited for developing an effective
PrEP [9,10]. That PrEP can prevent sexual transmission is
substantiated by the early studies in non-human primates which
employed daily oral administration of RT inhibitors TDF and/or
FTC [11,12,13]. This concept has reached clinical trials in which
tenofovir is currently being investigated for its prophylactic efficacy
[4]. The results of these studies are pending. As can be seen,
evaluation of different drug candidates for PrEP has taken a
momentum and it is necessary to continually evaluate new
candidates for this purpose since a PrEP with proven protective
efficacy now may not retain its effectiveness in the future years
given the propensity of HIV to develop drug resistance. While the
monkey model has been very useful in evaluating appropriate
candidate PrEPs, there are a number of limitations for its use to
screen large numbers of potential candidates [14,15]. Chief among
these is that it does not use HIV itself for challenge studies in
addition to being expensive. This somewhat restricts its predictive
value given that many of the present drugs are designed to be
specifically effective against HIV, not SIV or SHIV viruses that
are used in monkey viral challenges. Furthermore, it is not possible
to test candidate PrEPs against genetically divergent and drug
resistant viruses that exist in the field.
Humanized mouse models that harbor HIV susceptible human
cells and are permissive for HIV infection can overcome these
important limitations. In this regard, the classical SCID-hu-PBL
humanized mouse model was utilized for early microbicide testing
[16,17,18]. However, due to low and variable infection rate by
vaginal route, it is not considered consistently reliable [19].
Recently there have been substantial improvements in the new
generation of humanized mouse models [20,21,22]. Transplanta-
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generation of immunodeficient mice with much lower innate




permitted higher human cell engraftment levels and sustained
multilineage human hematopoiesis [20,21]. Additionally, another
model, the BLT mouse model, was developed by a modification of
the standard SCID-hu model. This involves transplantation of
thymic and liver tissues under the kidney capsule of NOD-SCID
mice followed by reconstitution with autologous human CD34
+
cells [23]. A number of groups including ours have demonstrated
the utility of these humanized mice as improved models for HIV-1
infection and CD4 T cell depletion [24,25,26,27,28,29]. Further-
more, these models also permit HIV-1 mucosal transmission via
both vaginal and rectal routes [30,31]. Thus it is now possible to
experimentally evaluate novel preventive strategies of HIV-1
sexual transmission exploiting these models.
In this context, it was recently shown that tenofovir could
prevent HIV-1 vaginal transmission using the BLT mouse model
[31]. Using the same model, it was also shown that systemic
administration of TDF (tenofovir) and FTC (emtricitabine)
prevents HIV-1 infection via vaginal and i/p challenges thus
setting the stage for large scale evaluation of different anti-HIV
compounds for their efficacy as PrEPs as well as topical
microbicides in preventing HIV infection [32]. Using RAG-hu
mice, here we evaluated two clinically approved compounds
namely, an integrase inhibitor raltegravir and a CCR5 inhibitor
maraviroc as a first step to determine their potential as PrEP
candidates [10,33]. Our results show that oral administration of
either of these drugs prevents HIV-1 infection via vaginal
challenge which is the major route of HIV-1 transmission.
Materials and Methods






2/2 (RAG-hu) mice were
prepared by engraftment with human fetal liver-derived CD34
+
hematopoietic progenitor cells as we previously described [26,30].
Mice were maintained at the Colorado State University Painter
Animal Center. These studies have been reviewed and specifically
approved by the CSU Institutional Animal Care and Use
Committee (Protocol 09-1460A). Briefly, newborn mice were
conditioned by irradiating with 350 rads and then injected
intrahepatically with 0.5-1610
6 human CD34
+ cells. Mice were
screened for human cell engraftment at 10–12 weeks post-
reconstitution. Peripheral blood was collected by tail bleed and
red blood cells were lysed by using the Whole Blood Erythrocyte
Lysing Kit (R&D Systems, Minneapolis, MN). The white blood
cell fraction was stained with antibodies against the human pan-
leukocyte marker CD45 (Caltag) and FACS analyzed to determine
the levels of human cell engraftment as we previously described
[26]. To assure efficient infection, mice with over 40% human cell
engraftment (as listed in Table 1) were chosen for vaginal viral
challenges.
Oral administration of anti-HIV drugs raltegravir and
maraviroc and HIV-1 challenge by vaginal route
Female RAG-hu mice were administered with either raltegravir
or maraviroc by oral gavage (6 mice each). Clinical formulations of
these drugs in tablet form (Maraviroc (Selzentry) 150 mg, Pfizer
Labs; Raltergravir (Isentress) 400 mg, Merck & Co) were freshly
dissolved in distilled water each day prior to oral gavage. Mouse
equivalent drug doses were calculated by using an interspecies
allometric scaling factor of 12.3 to arrive at 164 mg/kg and
62 mg/kg doses for raltegravir and maraviroc respectively [34,35].
Mice (six per group) received either raltegravir (3.28 mg per 20
gram mouse) or maraviroc (1.23 mg per 20 gram mouse) by oral
gavage daily. Mice were challenged with HIV-1 vaginally on the
4
th day of treatment and the drug treatment continued for 3 more
days. For vaginal viral challenges, cell-free HIV-1 strain BaL-1 (R5
tropic virus) contained in the original media used to produce the
virus (RPMI 1640 medium supplemented with 10% fetal bovine
serum) was used. Vaginal infections were performed in a volume of
20 ml (3000 TCID of BaL-1 virus). Sterile P200 tips that had been
previously heated over a flame to smooth any abrasive surfaces
were used to deliver the virus [30]. Anesthetized mice were held in
an inverted position for four minutes post-inoculation to allow
virus to adsorb and to prevent immediate discharge of virus.
Control non-treated mice (n=7) were also challenged similarly by
the vaginal route. Mice were observed daily and blood samples
drawn weekly to assess plasma viremia.
Measurement of viral loads
To detect HIV-1 in plasma of infected mice by Q-RT-PCR,
RNA was extracted from 25–50 ml of EDTA-treated plasma using
the QIAamp Viral RNA kit (Qiagen, Valencia, CA). Q-PCR was
performed using a primer set specific for the HIV-1 LTR sequence
and a corresponding LTR specific probe as described previously
[30,36]. To detect integrated virus, cellular DNA was extracted
using Qiagen kit. The cellular DNA was subjected to Q-PCR to
determine the proviral loads.
Flow cytometry
Whole blood was collected and red blood cells lysed as reported
previously [26,36]. Peripheral blood cells were stained for hCD3-
PE and hCD4-PECy5 (Caltag) markers and analyzed using a
Coulter EPICS XL-MCL FACS analyzer (Beckman Coulter,
Fullerton, CA). CD4
+ T cell levels were calculated as a ratio of the






+ T cell ratios, all mice were analyzed prior to
infection.
Results
Oral administration of integrase inhibitor raltegravir
protects humanized mice from HIV-1 infection via vaginal
challenge
We have previously shown that RAG-hu mice are susceptible to
HIV-1 infection via both vaginal and rectal routes [30]. Here we
used this model to determine if systemic administration of
raltegravir protects against vaginal HIV-1 challenge.
Mice were administered with the drug daily by oral gavage since
this drug is taken orally in a clinical setting. Vaginal viral challenge
was performed on the 4th day and the drug treatment continued
for three more days. To determine the status of HIV infection,
mouse plasma and cellular blood fractions were analyzed by Q-
PCR on a weekly basis. Our results showed that all of the non-
treated infected mice became virus positive by the 5th week post
challenge (Fig. 1A). Persistent viremia in plasma and proviral loads
in the cellular fractions were observed throughout the evaluation
period with viral loads reaching up to 10
6 copies/ml (Fig. 2). In
contrast, none of the raltegravir treated mice became infected at 5
weeks post-viral challenge unlike the non-treated mice (Fig. 1A).
Since it is possible that the drug treatment might have delayed the
onset of infection, mice were followed for an additional 5 weeks.
No evidence of infection was seen throughout the 10 week
observation period as evaluated by either RNA or DNA PCR
(Fig. 2). These data collectively suggest that oral administration of
Oral HIV Prophylaxis by Raltegravir and Maraviroc
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regard to any adverse effects such as loss of appetite or weight loss,
none was noted during the entire experimental period and the
mice appeared normal.
Oral administration of CCR5 inhibitor maraviroc protects
humanized mice from HIV-1 infection via vaginal
challenge
In addition to the viral integrase inhibitor raltegravir, we also
evaluated a CCR5 antagonist maraviroc to determine its efficacy
in preventing HIV-1 infection via vaginal challenge using a similar
protocol like above. This experiment was done at the same time
and the same non-treated virus infected animals were used as
controls. Maraviroc was also administered orally like above in a
similar time scale. Our results showed that while all the seven
control untreated mice became virus positive by the fifth week,
none of the six maraviroc treated mice became infected
throughout the ten week observation period (Fig. 1B). Both
RNA PCR to detect plasma viremia and DNA PCR to detect
integrated provirus in blood cellular fractions were negative in
maraviroc treated mice in contrast to non-treated virus challenged
mice (Fig. 3). These results showed that oral administration of
maraviroc fully protects humanized mice against vaginal infection.
Table 1. Summary of human cell engraftment levels in humanized (RAG-hu) mice*.
Uninfected Control Non-Treated
Mouse Gender %Engraftment Mouse Gender %Engraftment
J667 Female 95 812 Female 91.6






Raltegravir Treated Maraviroc Treated
Mouse Gender %Engraftment Mouse Gender %Engraftment
J683 Female 43.6 J672 Female 74.3
J682 Female 47 J671 Female 65.8
J681 Female 60.5 J670 Female 80.4
J680 Female 62.6 J642 Female 81.1
J637 Female 83.5 J641 Female 62.4
J636 Female 70 J640 Female 67.2
*Peripheral blood was collected from human CD34 cell reconstituted mice at 10–12 weeks post engraftment. White blood cell fraction was stained with human CD45
FITC conjugated antibody and analyzed by FACS to confirm human cell engraftment prior to drug treatments and vaginal HIV challenges.
doi:10.1371/journal.pone.0015257.t001
Figure 1. Oral administration of raltegravir or maraviroc protects humanized mice against vaginal HIV-1 challenge. RAG-hu mice
were challenged by vaginal route after oral administration of raltegravir or maraviroc as described in Methods. Blood was collected weekly from
infected mice and the status of HIV-1 infection was determined by Q-RT-PCR. The viral challenge experiments were performed at same time for both
of the drugs and the same set of control non-treated infected mice were used for comparison. Kaplan-Meier plots of time course of appearance of
viremia in drug treated versus non-treated virus challenged mice. A. Raltegravir treated B. Maraviroc treated.
doi:10.1371/journal.pone.0015257.g001
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raltegravir and maraviroc treated mice following vaginal
infection
The above criteria of viral detection showed that both
raltegravir and maraviroc treated mice were fully protected from
vaginal HIV-1 challenge. Since CD4 T cell loss is a main
characteristic of HIV-1 infection in humanized mice akin to that
seen in the human, we further evaluated the virus challenged mice
for any evidence of such loss [26,36]. Accordingly, peripheral
blood was collected weekly and subjected to FACS analysis.
Baseline CD4 T cell levels for each of the experimental mice were
determined prior to viral challenge and these values were
compared to the levels post-viral challenge. While there was a
clear pattern of CD4 T cell decline in un-treated mice, their levels
were stable in both groups of mice receiving raltegravir or
maraviroc further confirming the absence of HIV-1 infection in
these mice (Fig. 4).
Discussion
Here we have shown that oral administration of two clinically
approved drugs namely, raltegravir or maraviroc fully protect
humanized mice against HIV-1 infection from vaginal viral
challenge suggesting their potential utility as PrEPs. These two
compounds have different modes of action [10]. Maraviroc is a
low molecular weight CCR5 antagonist which inhibits the binding
of the natural ligands of CCR5, namely chemokine ligand 3
(CCL3 also known as MIP-1a), CCL4 (MIP1-b) and CCL5
(RANTES) [37]. It is a functional CCR5 antagonist devoid of
agonist activity and shown to have a long lasting physical and
functional occupancy of CCR5 leading to sustained antiviral
activity [38]. It has been shown to have potent effect against all R5
tropic viruses representing various viral clades in addition to being
effective against a wide range of drug resistant viruses [39].
Topical vaginal application of maraviroc as a microbicide was
recently shown to protect rhesus monkeys against SHIV virus
Figure 2. RNA and DNA viral loads in mice administered with raltegravir. RAG-hu mice were challenged by vaginal route after oral
administration of raltegravir as described in Methods. Blood was collected weekly. Viral RNA was extracted from the plasma fraction and DNA was
extracted from the cellular fraction. Viral RNA and DNA loads were determined by Q-RT-PCR as described in methods. A. RNA viral loads B. DNA viral
loads.
doi:10.1371/journal.pone.0015257.g002
Figure 3. RNA and DNA viral loads in mice administered with maraviroc. RAG-hu mice were challenged by vaginal route after oral
administration of raltegravir as described in Methods. Blood was collected weekly. Viral RNA was extracted from the plasma fraction and DNA was
extracted from the cellular fraction. Viral RNA and DNA loads were determined by Q-RT-PCR as described in methods. A. RNA viral loads B. DNA viral
loads.
doi:10.1371/journal.pone.0015257.g003
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that interferes with the viral DNA integration which is an essential
step in viral replication. It is active against multidrug-resistant and
both CCR5-tropic and CXCR4-tropic HIV-1 strains [33,41]. To
our knowledge this is the first report evaluating these two drugs as
potential systemic PrEPs against HIV-1 vaginal transmission.
To simulate the clinical situation in mice, we administered each
of the drugs orally as the prescription suggested for human use
thus permitting intestinal absorption and reaching systemic
effective concentrations. With regards to oral dosing in these
proof-of-concept studies, we treated the animals for three days
with the drug to achieve a systemic drug equilibrium in vivo prior
to vaginal challenge and continued the drug treatment for an
additional four days. This is similar to the studies of Denton et al in
BLT mice that employed FTC/TDF (Truvada) for PrEP testing
[32]. Whereas the drug combination FTC/TDF (Truvada) was
injected i/p to the mice to demonstrate PrEP efficacy in the above
studies, we used oral administration as clinically suggested for the
above drugs. While all the control non-treated, vaginally HIV-1
challenged mice became infected within five weeks, none of the
raltegravir or maraviroc treated mice (6 mice each) showed any
evidence of infection. Furthermore, DNA extracted from splenic
tissue samples after euthanizing the mice at sixteen weeks post-
challenge also did not show any evidence of infection by PCR
analysis (data not shown). Thus protection conferred by either of
these two drugs is highly significant (p value 0.0006, Fisher’s exact
test). Since both maraviroc and raltegravir treatments fully
protected against vaginal challenge, this also confirmed that
effective protective concentrations for both these drugs were
reached and maintained in the vaginal tissues during the oral
dosing period. We further evaluated the mice for evidence of
helper CD4 T cell loss which is a characteristic hallmark of HIV-1
infection. As expected, a declining trend for CD4 T cell counts was
observed in control non-treated mice in contrast to either of the
treatment groups receiving raltegravir or maraviroc (Fig. 4). These
data collectively showed that treated mice resisted vaginal viral
challenge thus indicating full protection in contrast to non-treated
mice.
Whereas topical microbicides received the major attention other
than vaccines to preventing HIV infection thus far with many
clinical trials currently ongoing in the field, experimental studies
on systemic PrEPs for HIV have been limited to very few
compounds with a main focus on RT inhibitors [13,42,43]. These
included tenofovir, emtricitabine and efavirenz which showed
efficacy in non-human primates against i/v, vaginal or rectal
challenges with either SIV and/or different versions of SIV/HIV
chimeric viruses [13,42]. In addition to showing efficacy in the
monkey models, the RT inhibitors tenofovir and emtricitabine also
showed efficacy in the BLT mouse model against HIV challenge
[32]. Based on the effectiveness of tenofovir as a PrEP in the
experimental studies it is currently in clinical trials to evaluate its
efficacy in the human [44]. With regard to fusion inhibitors, oral
administration of CMPD167, a small molecule CCR5 inhibitor,
protected macaques against vaginal SHIV viral challenge [45]. As
can be seen, there is a paucity of number of compounds tested for
systemic PrEP.
Our present results have provided the proof-of-concept data for
further investigating the potential of raltegravir and maraviroc as
PrEPs thus identifying additional novel class of molecules with
different modes of action [4,10]. Based on their proven broad
spectrum of activity against divergent HIV strains in the clinic,
both these drugs make excellent candidates for PrEP. Future
studies should evaluate variations in the dose, timings of drug
administration prior to vaginal challenge and duration of efficacy
without further dosing after viral challenge to determine the
memory effect. It is also necessary that field and drug resistant
viruses be tested in this humanized mouse model. Furthermore,
use of more than one drug in any PrEP will be more effective in
field conditions. This can also be tested in this mouse model using
a combination of raltegravir and maraviroc to derive pre-clinical
data. Such evaluations will fine tune the PrEP regimens to be more
practically applicable for clinical testing.
In addition to the systemic PrEP, another highly promising
method of prevention of HIV-1 sexual transmission is the topical
use of effective microbicides as mentioned above. Therefore,
testing of raltegravir and maraviroc as topical microbicides in the
RAG-hu mouse model of sexual HIV-1 transmission is likely to
provide critical pre-clinical data in this context as well.
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